Atropine has almost disappeared from routine anaesthetic practice, but is increasingly recommended and used for intubation of critically ill children. We sought to determine the influences on atropine use during critical care intubation by a group of 61 paediatric intensivists from eight countries in Europe and North and South America, using a Delphi approach. In addition, we wished to establish whether it was possible to give recommendations for atropine use. An expert panel examined clinical indicators or outcomes and atropine-prescribing practices, which potentially could influence atropine prescription. The indicators were formatted into Likert-type questionnaires before being answered by the intensivists in two rounds of structured questioning, with qualitative and quantitative feedback. A stratification into frequent, intermediate and infrequent users, was constructed, according to the frequency of atropine use. Consensus was considered to have been achieved for a median score of ≥7 with ≥75% agreement. We found three areas of consensus: personal practice determines atropine use; there is a risk of death during critical care intubation; and the presence of fever should not influence atropine use. A near-consensus was reached that children are at risk of haemodynamic disturbance. Importantly, there was no consensus that the use of atropine prevents either bradycardia or reduces the risk of hypotension or death during intubation. The use of atropine to prevent haemodynamic instability during intubation remains controversial and consensus was not forthcoming, despite agreement on several risk factors. In particular, the usefulness of atropine to prevent bradycardia, hypotension or death during critical care intubation remains uncertain.
Introduction
Atropine has been recommended to be used as premedication for anaesthesia from as early as the 1950s, to attenuate vagallymediated or drug-induced bradycardia during induction and laryngoscopy. 1, 2 Later studies showed the advantage of atropine in maintaining cardiac output during halothane induction. 3 The subsequent transition to less bradycardia-inducing anaesthetic inhalation agents and non-depolarising muscle relaxants 4 led to the rejection of the routine use of atropine.
In contrast, several recent reviews have recommended that neonates [6] [7] [8] and children under five years 9 should receive atropine prior to critical care intubation, and the American College of Critical Care Medicine has specifically recommended its use for intubation in cases of septic shock in neonates and children. 10 The above recommendations are based on the opinions of a small number of authors (with the exception of that for septic shock) and have appeared without any recommended clinical outcome or clinical trials of the efficacy or side-effects of atropine in the paediatric intensive care population. 11 Currently, the use of preintubation atropine is an increasing trend in neonatology, as is illustrated by the one recent survey which noted that approximately half of all UK tertiary neonatal units use atropine routinely. 12 Qualitative research methods, such as the Delphi method, obtain consensus where scientific evidence is inconclusive or contradictory as is the case premedication with atropine in paediatric critical care. The Delphi method seeks to establish a quantitative assessment of the level of agreement with a statement among a group of experts by a process of 'rounds' of structured questioning combined with a system of anonymous, iterative feedback. This feedback enables the participants to modify their opinion with respect to that of the group while ensuring that no one participant can dominate the final outcome. 13 An advantage of the Delphi Method is that the opinions of a large number of individuals in diverse locations with differing experience and backgrounds can contribute towards enhanced decision-making. A disadvantage is that it does not provide quantitative data and so cannot replace the need for clinical trials. 14 Our objective was to use a Delphi approach to determine the qualitative influences on atropine use during critical care intubation by a group of both highly experienced and relatively inexperienced paediatric intensivists in geographically diverse locations. We modified the Delphi technique to examine atropine-prescribing practices, to determine whether it was possible to establish recommendations for the use of atropine by means of stratification according to the frequency of atropine prescription.
An international Delphi survey on the use of atropine for critical care intubation Methods
An expert panel of three paediatric intensivists and a clinical epidemiologist examined clinical indicators influencing atropine prescription and the influence of atropine on clinical outcomes. They proposed nine indicators, which were formatted into statements contained in the round 1 questionnaire, using a Likert-type scale to assess level of agreement with the statement. Independent English and French reverse translations were used to verify the accuracy of the questionnaire and all other written material. The members of the expert panel were thereafter excluded from participation in the study (Figure 1 ).
An international group of paediatric intensivists, or 'user group,' was brought together by five of the co-authors (PJ, SD, NK, JC, MJP), who then answered the questionnaires between March 2010 and April 2011. The aim was to include a broad range of age and experience, as has been previously recommended. 13, 15 The absolute prerequisite was that each paediatric intensivist should have two or more years experience in paediatric intensive care and/or paediatric intensive care transport. Importantly, no information was collected regarding atropine prescribing practices prior to recruitment. Agreement to participate in the survey was given by all the paediatric intensivists when they replied to the round 1 questionnaire, which included a letter explaining the functioning of the Delphi methodology. No financial incentive was offered.
The paediatric intensivists were contacted personally or by email and replied to questionnaires principally by e-mail, although sometimes by fax. All the UK, USA and Brazilian paediatric intensivists used English translations and the French, Swiss and Dutch participants used French translations. The Canadian paediatric intensivists used either English or French translations according to their preference. The opinions of the paediatric intensivists regarding influences on the prescription of atropine were rated according to their level of agreement, or non-agreement, with the indicators chosen by the expert panel. The Likert scale rated indicators where '1' indicated strong disagreement and '9' strong agreement. In addition, the paediatric intensivists were encouraged to provide written comments. Non-responders were motivated to participate through e-mail contacts, in person or by phone by the principal author or the co-author who had recruited them.
Respondents' answers were rated according to the quantitative level of agreement with the question at the end of round 1 (median score) and agreement with each other (percentage of respondents agreeing with a median of ≥7). Three categories of agreement were possible: 1-3 where there was a consensus of non-agreement, 4-6 where there was no consensus and 7-9 where there was a consensus of agreement. Round 1 questions rated above the cut-off, with a median score of ≥7 and a consensus of ≥60% agreement could be developed into new questions to examine other influences on atropine prescription. The comments obtained from the user group were Figure 1 Process of the survey. The formation of the questionnaire on the influences on atropine prescription was followed by two rounds of questions and structured feedback with a final rating process and stratification for analysis.
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considered to be new round 1 questions. The round 1 questions that were rated below the cut-off entered directly into round 2 (Figure 1) .
The round 2 questionnaire included quantitative feedback in the form of the individual' s previous response to the question and the median and distribution of the user group. Qualitative feedback of the longhand comments was provided anonymously in the form of a résumé. The purpose of the feedback contained in the round 2 questionnaire was twofold, to enable the paediatric intensivist to confirm their previous response and to permit them to change their responses with regard to the responses of the other paediatric intensivists. A group conversation between the intensivists was not facilitated as is sometimes a feature of the Delphi technique, because of the differing time zones, which would have inevitably been biased by the views of those most freely able to participate. 13 At the end of Phase II, a final rating process was used to select those indicator/s with a median score of ≥7 with a consensus of ≥75%, as previously used by Shield et al. 16 Those questions with a median ≤3 and a consensus of ≥75% were considered to have obtained a negative consensus. During round 2, each paediatric intensivist was asked to confirm their estimated frequency of atropine use.
The user group was stratified according to the declared estimated frequency of use of atropine in the following three stratified groups; 'frequent users' (2/3 to all the time), 'intermediate users' (1/3 to 2/3 of the time) and 'infrequent users' (0 to 1/3 of the time). For the purposes of analysis, the frequent users group was chosen as the reference against which the two other groups' answers were compared.
Statistical analysis
Continuous variables were expressed as a mean (± standard deviation) or median (inter-quartile range) according to their distribution, and quantitative variables were expressed as a percentage (%). A Wilcoxon test was used to compare the median score of the user group answers and a Chi-squared test to compare qualitative variables using SAS 9.2 software (Cary, North Carolina, USA).
Results
Seventy-five paediatric intensivists were approached to participate in the user group, of whom 68 completed the round 1 questionnaire. One was excluded because the respondent had less than two years' experience. Ninety-one percent (61/67) replied to the round 2 questionnaire (Figure 1) . Overall, only three intensivists (5%) participated who had less than five years' experience, and the distribution of experience was similar between the three prescribing groups ( Table 1 ). The distribution of the 61 according to country is described in descending order: France (34), USA (9), UK (8), Canada (6), Brazil (2) and Switzerland (2). Forty-nine percent (30/61) of the user group estimated they used atropine for less than half of intubations. Nineteen (31%) were 'frequent users' of atropine (2/3 to all the time), 18 (30%) were 'intermediate users' (1/3 to 2/3 of the time) and 24 (39%) were 'infrequent users' (1/3 to never). There were no significant differences between the three stratified groups with respect to gender, geographical location (divided into two groups of countries; Continental Europe or the Americas and UK), age or number of years' experience ( Table 1) .
After round 1, five indicators met the previously determined criteria to be expanded for development of new questions. These were: • whether it was a personal decision to prescribe atropine (Q2, • the drugs used for induction(Q7 Table 2) • the pathology (Q8, Table 2) • the influence of atropine on bradycardia (Q9, Table 3 ).
The influence of a temperature greater than 38.5°C achieved a consensus of non-agreement after round 1 (median 1, 92% agreement, Q6, Table 2 ).
Of the five indicators above, only whether it was a personal decision to use atropine achieved consensus, with a median of 7 with 62% agreement in round 1 compared to median 8 with 81% agreement in round 2 (Q2, Table 2 ). The indicators of age, induction drug and pathology all retained a median of 7 during round 2 and slightly increased their levels of agreement: 60 to 64% for age, 61 to 67% for induction drug and 60 to 61% for pathology, none of them achieving final consensus (Q5, 7, 8, Table 2 ). The risk of death during intubation achieved consensus when it was first put in round 1, median 8 with 80% agreement compared to median 8 with 82% in round 2, and that for hypotension, median 8 with 72% agreement versus round 2 median 8 with 74% agreement (Q10, 12, Table 3 ). There was no consensus that atropine reduces the risk of death (median 4 with 41% agreement) or hypotension at the end of round 2 (median 3 with 52% agreement) (Q11, 13, Table 3 ).
The influence of age achieved a round 2 median score of 7, with 64% agreement (Q5, Table 2 ). When the question was narrowed to whether the practice of the paediatric intensivists was to use atropine for children aged less than six months, the answer achieved the same median score, with 70% agreement (Figure 3) . The prescribing practices for induction drugs and pathologies are illustrated in 
Discussion
Our study revealed a clear consensus for three indicators. This group of paediatric intensivists agreed that it was their personal decision whether to use atropine (Q2, Table 2 ), that there is a risk of death during critical care intubation (Q12, Table 3 ) and there is a consensus that fever should not influence the decision to use atropine (Q6, Q10, I believe that children are at risk of 74% 79% 61% 79% hypotension (according to your definition) during 8 (6-9) 8 (7-9) 7.5 (6-9) 9 (7-9) emergency intubation Q11, The use of atropine during emergency 13% 21% 17% 4% intubation reduces the risk of hypotension 3 (1.5-5) 5 (3-6) 5 (3-6) 2 (1-2.5) * (according to your definition) during the procedure Q12, I believe that children are at risk of dying 82% 84% 83% 87% during emergency intubation 8 (7-9) 8 (7-9) 7.5 (7-9) 8.5 (7) (8) (9) Q13, The use of atropine during emergency 10% 26% 0% 4% intubation reduces the risk of dying during 4 (2-6) 5 (4-7) 4.5 (3-6) 2 (1-4.5) * the procedure * = p<0.05 Table 3 Results of the round 2 questions relating to the potential clinical outcomes of intubation and influences on atropine prescription on clinical outcomes. The user group is divided according to the frequency of atropine prescription into the stratified groups of frequent, Intermediate and Infrequent users. The intermediate and Infrequent users are compared against the reference of the frequent users.
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haemodynamic disturbance (Q10, Table 2 ). Importantly, there was no consensus by the user group as a whole or in any of the stratified groups that atropine prevents either bradycardia (Q9, Table 3 ) or reduces the risk of hypotension (Q11, Table 3 ) or death (Q13, Table 3 
).
A recent survey of the Delphi method noted that only 13% of published articles included participants from more than one country. 15 Despite recruiting a number of paediatric intensivists from six countries, there was an over-representation of French intensivists. This was due to the ease of recruitment of this population and potentially limits the general applicability of the results. We achieved an even distribution of age and experience by group of country for the three stratified groups and sustained a high level of participation (91%), which is above average. 15 We deliberately modified the technique from using only very experienced doctors to include the views of relatively junior intensivists with less than five years PICU experience, who have a high presence at the bedside.
Quantitative methodologies have the advantage of being able to provide information regarding potential differences between therapies. One of their disadvantages is that their conclusions are drawn from populations that may be heterogeneous. Subsequent meta-analyses can be used to enhance impact. The difference with a qualitative methodology is that the importance of years of individual practice, local teaching, discussion, non-scientific bedside testing as well as opinion of scientific literature can be assigned a quantitative value. 13 The Delphi methodology is well-established but, like other quantitative methodologies, may fail to give clear results either because of the structure of the questionnaire or anomalies in the selection of the participants or because consensus does not exist. 14 It is only possible to speculate why so little agreement was forthcoming from our results, particularly with regard to the use of atropine with specific pathologies or drugs. Perhaps there is a critical threshold of literature required for a body of opinion to be formed, and this is not the case for our subject. The overall deficiency in convergence of opinion may be related to intransigently held views of intensivists as a population, as opposed to other specialties, although this should not be taken as a comment on the general applicability of the Delphi methodology in intensive care medicine.
The most important bias in the survey is the relationship between influence on prescribing and prescribing itself. Both are subjective judgements and there is no way of separating their influence on each other. There are several reasons why we did not achieve consensus after round 2 for more of the indicators. Firstly, and most importantly, while the inclusion of heterogeneous opinions was beneficial in generating validity of the results in our survey, the infrequent users responded almost universally with low scores to all questions. 13, 15 This was both a strength and a weakness, as it reduced the possibility of obtaining consensus. The second reason is that there was very little drift towards consensus between the two rounds. That the paediatric intensivists did not change their responses between rounds 1 and 2 shows the stability of their opinions. A third reason is linked to the methodology, where the questions regarding the 'influences' of, for example, induction drugs on atropine prescription, can be interpreted positively; when the question is rephrased to determine associations between atropine prescription and, for example, ketamine, some paediatric intensivists may be positively influenced to prescribe atropine with ketamine whereas others may be negatively influenced.
The most sensitive methodological issue with the Delphi technique is determining what the correct level of consensus should be. 15 The level of consensus is chosen a priori by the investigators and may vary across studies, with consequences for the conclusions of the study. There is currently no quantitative evidence of what constitutes a significant level of agreement. 15 Our a priori use of a 60% agreement cut off during the initial rating process meant that the uniform agreement of the frequent users and the intermediate users was just able to assure the development of an indicator by virtue of their relative proportion in the study population (37/61, 60%). In practice, however, the selection of an indicator required a high level of agreement among the frequent and intermediate users with the participation of at least some of the infrequent users. The use of a cut off of 75% for the final rating process meant that any final consensus needed the substantial participation of all three stratified groups including infrequent users. It is not unexpected that the age of the child influences the administration of atropine, even if there was no overall consensus achieved (Figure 2 and Q5, Table 2 ). In the early months of life, there is predominant parasympathetic autonomic activity due to dense innervation of the sino-atrial node, associated with poor innervation of the ventricles and conduction bundles, 17 which increases the likelihood of vagally-mediated reflex bradycardia during intubation. 18 Overall, the user group complied poorly with the 2002 Paediatric Advanced Life Support (PALS) guidelines that all children <1 year and children 1-5 years receiving suxamethonium should also receive atropine (Figure 2) . 19 Recent guidelines do not give specific recommendations for drugs for rapid sequence induction.
The one consensus of non-agreement is about the influence of fever (Q6, Table 2 ). The pro-hyperthermic activity of atropine is due to its ability to diminish sweating; this is a well known complication in the tropics, where high ambient temperatures and humidity can raise body temperature during anaesthesia. 20 This is unlikely to be a problem where ambient temperatures are moderate and so it is unsurprising that intensivists did not see this as a contraindication to prescription.
The only pathology for which atropine has been specifically recommended is septic shock, which failed to achieve a 75% consensus among the practice of any of the three groups of prescribers (Figure 2) . 10 Indeed, a consensus was not achieved for any of the other pre-existing pathologies or induction drugs that were mentioned by the paediatric intensivists in round 1 (Figure 2 and 3) . Use with suxamethonium remains one area of practice where anaesthetists use atropine routinely, at least for repeat doses 21 and several published articles clearly indicate the risk of severe vago-mimetic bradycardia and/or cardiac arrest due to use of suxamethonium alone. 1, 22 In contrast, nondepolarising muscle relaxants have been associated with an attenuation of vagal bradycardia, so the use of atropine is probably not indicated. 4 Although the use of ketamine has been described for anaesthetic premedication 23 and Emergency Department sedation 24 the methodology of these studies does not enable a decision to be made as to the value of combining ketamine and atropine.
The intermediate users could perhaps be better described as the 'discerning' users because they attained 78% agreement (Q3, Table 2 ) regarding whether 'recommendations from the literature' influenced their decision to use atropine, much higher than the frequent (37%) and infrequent users (36%). They agreed that age (78%), pathology (72%) and the use of induction drugs (83%) influenced their prescribing habits, again more often than either the frequent and infrequent users. When they were questioned regarding their practices, they tended to agree with one or other of the groups (Figures 2 and 3) . As such, this group is potentially the best guide to practice.
The outcome measures for intubation in paediatric critical care 25, 26 or routine anaesthetic 27 intubation have classically been regarded as changes in heart rate because of the high frequency of vagal bradycardia. As such, it is surprising that none of the stratified groups achieved consensus after round 2 that atropine prevents bradycardia (Q9, Table 3 ). One retrospective study in a paediatric population noted a 4% incidence with and without atropine, 26 although neonatal studies have demonstrated more clearly the effectiveness of atropine to prevent bradycardia during intubation. 28 New questions were not posed about preferred therapy when bradycardia is encountered during intubation. This is a limitation of the Delphi methodology, where new questions are dependent on free text comments from previous rounds.
In contrast, outcomes of adult studies have focussed on the risk of death or hypotension during intubation. 29, 30 Consensus was achieved by all three stratified groups that there is a risk of death, and consensus was nearly achieved that there is a risk of hypotension during critical care intubation (Q10, 12, Table 3 ). However, none of the three groups considered that atropine had an effect on either of these two outcomes, not even the frequent users, which is perhaps our most important finding (Q11, 13, Table 3 ).
Conclusion
In summary, despite our demonstration of consensus with regards to some indicators, our survey exposes that the widespread variation in atropine prescription is dependent on personal opinion rather than scientific literature. The Delphi method was unable to distinguish clear areas of consensus for prescribing with drugs and pathologies, which does not enable the formulation of recommendations for critical care intubation. In addition, the methodology employed diminished the capacity to achieve positive consensus because the infrequent users responded regularly with low scores to all questions. The intermediate users are perhaps the most discerning users, who generally prescribe atropine for children aged less than six months and when using suxamethonium, as did the frequent users. The intermediate users did not prescribe atropine when using ketamine or rocuronium and when intubating older children or those with a full stomach, as for the infrequent users. Importantly, no consensus was achieved by any of the groups about the potential benefit of atropine in reducing the risk of hypotension or death associated with intubation.
